Inhibitors of cyclin dependent kinase 7 (cdk7)
US-2024360165-A1 · Oct 31, 2024 · US
Aromatic heterocyclic compound, pharmaceutical composition, and use thereof
US12540149B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12540149-B2 |
| Application number | US-202118259029-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 27, 2021 |
| Priority date | Dec 24, 2020 |
| Publication date | Feb 3, 2026 |
| Grant date | Feb 3, 2026 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An aromatic heterocyclic compound, a pharmaceutical composition and use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt of any one of the foregoing, or a crystal form or solvate of any one of the foregoing. The aromatic heterocyclic compound has a novel structure, good CDK7 inhibitory activity, and good selectivity.
First claim
Opening claim text (preview).
What is claimed is: 1 . A compound or a pharmaceutically acceptable salt thereof, or a crystal form or solvate of any one of the foregoing, wherein the compound is selected from the group consisting of: 2 . A compound or a pharmaceutically acceptable salt thereof, or a crystal form or solvate of any one of the foregoing, wherein the compound has the following structure: 3 . A compound or a pharmaceutically acceptable salt thereof, or a crystal form or solvate of any one of the foregoing, wherein the compound has the following structure:
Assignees
Inventors
Classifications
at least one of the hetero rings does not contain nitrogen as ring hetero atom · CPC title
Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title
- C07D471/04Primary
Ortho-condensed systems · CPC title
- A61P35/00Primary
Antineoplastic agents · CPC title
- C07F9/65583Primary
each of the hetero rings containing nitrogen as ring hetero atom · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12540149B2 cover?
- An aromatic heterocyclic compound, a pharmaceutical composition and use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt of any one of the foregoing, or a crystal form or solvate of any one of the foregoing. The aromatic heterocyclic compound has a novel structure, good CDK7 inhibitory act…
- Who is the assignee on this patent?
- Recursion Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D471/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 03 2026 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).